Breaking News, Collaborations & Alliances

Q BioMed Initiates GMP Production of Novel COVID-19 Therapeutic

COVID-19 clinical trial planned for Q1 2021 supported by Canadian Government.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Q BioMed Inc., a commercial-stage biotech company, said that with its technology partner, Mannin Research, a GMP production contract has been initiated for MAN-19, a clinical-grade therapeutic intended to treat complications caused by COVID-19. The Phase 1 clinical trial is slated to begin patient enrollment in February 2021.   The accelerated development of this novel virus-agnostic and host-directed therapeutic is being supported in part by funding from the Canadian and German governments unde...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters